 |
160 Products |  |
813 Diseases | | 160 Products |
|
1552 Trials |  |
75151 News |  |
| «12...3132333435363738394041...858859» |
- |||| Vectibix (panitumumab) / Amgen
Biomarker, Trial completion date, Trial primary completion date: An Additional Analysis of Data from the PARADIGM Exploratory Study (NCT02394834) in Patients with Advanced/Recurrent Colorectal Cancer (clinicaltrials.gov) - Sep 20, 2024
P=N/A, N=757, Recruiting, Sponsor: Takeda
Trial completion date: Jul 2024 --> Jul 2027 | Trial primary completion date: Jul 2024 --> Jul 2027
- || Lonsurf (trifluridine/tipiracil) / Otsuka
Trial completion date, Trial initiation date, Trial primary completion date: TRIFLUOX-DP: Safety of Trifluridine/Tipiracil in Patients With Dihydropyrimidine Dehydrogenase Deficiency Diagnosed With Metastatic Colorectal or Gastroesophageal Cancer (clinicaltrials.gov) - Sep 20, 2024
P2, N=73, Not yet recruiting, Sponsor: UNICANCER
Trial completion date: Jul 2024 --> Jul 2027 | Trial primary completion date: Jul 2024 --> Jul 2027 Trial completion date: Jun 2028 --> Oct 2028 | Initiation date: Jun 2024 --> Oct 2024 | Trial primary completion date: Jun 2026 --> Oct 2026
- Xtandi (enzalutamide) / Pfizer, Astellas, FG-3246 / Fortis Therap, FibroGen
Phase classification: FOR46 in Combination With Enzalutamide in Patients With Metastatic Castration Resistant Prostate Cancer (clinicaltrials.gov) - Sep 20, 2024
P1/2, N=36, Recruiting, Sponsor: Rahul Aggarwal
Trial completion date: Jun 2028 --> Oct 2028 | Initiation date: Jun 2024 --> Oct 2024 | Trial primary completion date: Jun 2026 --> Oct 2026 Phase classification: P1b/2 --> P1/2
- | Journal, IO biomarker: Construction and clinical significance of prognostic risk markers based on cancer driver genes in lung adenocarcinoma. (Pubmed Central) - Sep 20, 2024
Phase classification: P1b/2 --> P1/2 This study identified 11 effective biomarkers, DE-CDGs, which can predict LUAD prognosis and explored the biological significance of CDGs in LUAD prognosis, immunotherapy, and treatment.
- | Tavneos (avacopan) / Amgen
Journal, Real-world evidence, Real-world: Avacopan in Anti-Neutrophil Cytoplasmic Autoantibodies-Associated Vasculitis in a Real-World Setting. (Pubmed Central) - Sep 20, 2024
This study identified 11 effective biomarkers, DE-CDGs, which can predict LUAD prognosis and explored the biological significance of CDGs in LUAD prognosis, immunotherapy, and treatment. No abstract available
- || Nplate (romiplostim) / Amgen, Doptelet (avatrombopag) / SOBI, Promacta (eltrombopag) / Novartis
Review, Journal: Thrombopoietin Receptor Agonists in Post-Hematopoietic Cell Transplantation Complicated by Prolonged Thrombocytopenia: A Comprehensive Review. (Pubmed Central) - Sep 20, 2024
However, eltrombopag remains the most extensively studied agent. TpoR agonists had promising effects in the treatment of post-HCT thrombocytopenia with a good safety profile so far, highlighting the potential benefit of their use.
- ||||| Enbrel (etanercept) / Pfizer, Amgen
Enrollment closed, Adherence: A Study to Learn About the Adherence and Clinical Outcomes in Colombian Patients With an E-Device for Etanercept Administration in Rheumatoid Arthritis (clinicaltrials.gov) - Sep 20, 2024
P=N/A, N=20, Active, not recruiting, Sponsor: Pfizer
TpoR agonists had promising effects in the treatment of post-HCT thrombocytopenia with a good safety profile so far, highlighting the potential benefit of their use. Recruiting --> Active, not recruiting
- | Stivarga (regorafenib) / Bayer
Enrollment change, Trial completion date, Trial termination, Trial primary completion date, Metastases: Study Of Intrabucally Administered Electromagnetic Fields and Regorafenib (clinicaltrials.gov) - Sep 20, 2024
P2, N=2, Terminated, Sponsor: Wake Forest University Health Sciences
Recruiting --> Active, not recruiting N=25 --> 2 | Trial completion date: Nov 2025 --> May 2024 | Suspended --> Terminated | Trial primary completion date: May 2025 --> May 2024; Slow accruals
- | Enbrel (etanercept) / Pfizer, Amgen
Journal, Oncolytic virus: IL-12-mediated toxicity from localized oncolytic virotherapy can be reduced using systemic TNF blockade. (Pubmed Central) - Sep 20, 2024
with tumor necrosis factor receptor 2 on hematopoietic cells. Critically, this unique mechanism allows for vPD1/IL-12-mediated toxicities to be alleviated through the use of US Food and Drug Administration (FDA)-approved tumor necrosis factor (TNF) blockers such as etanercept.
- | botensilimab (AGEN1181) / Agenus, balstilimab (AGEN2034) / Agenus
Trial initiation date: BBOpCo: Botensilimab and Balstilimab Optimization in Colorectal Cancer (clinicaltrials.gov) - Sep 20, 2024
P2, N=15, Not yet recruiting, Sponsor: Nicholas DeVito, MD
Critically, this unique mechanism allows for vPD1/IL-12-mediated toxicities to be alleviated through the use of US Food and Drug Administration (FDA)-approved tumor necrosis factor (TNF) blockers such as etanercept. Initiation date: Jul 2024 --> Oct 2024
- || Prolia (denosumab) / Amgen
Review, Journal: The use of denosumab in osteoporosis - an update on efficacy and drug safety. (Pubmed Central) - Sep 20, 2024
Although bisphosphonates are often selected as initial therapy for osteoporosis, denosumab may be an appropriate initial therapy in patients at high risk for fracture, including older patients who have difficulty with the dosing requirements of oral bisphosphonates, as well as patients who are intolerant of, unresponsive to, or have contraindications to other therapies. Additional data is needed to address questions regarding treatment duration and discontinuation.
- || Review, Journal: B-cell Depletion Therapy in Pediatric Neuroinflammatory Disease. (Pubmed Central) - Sep 20, 2024
B-cell depletion therapies can be safe and effective in pediatric patients. Anticipation and mitigation of common adverse effects through primary prevention strategies, close monitoring, and appropriate symptomatic management can improve safety and tolerability.
- || Review, Journal: Injection site reactions resulting from the use of biological therapy in the treatment of moderate-to-severe plaque psoriasis. (Pubmed Central) - Sep 20, 2024
The choice of biologic agent should consider ISR risk. Education on injection techniques and the use of single-dose autoinjectors/pens can mitigate ISR risk.
- | Ibrance (palbociclib) / Pfizer
Retrospective data, Journal: Potential association of SULT2A1 and ABCG2 variant alleles with increased risk for palbociclib toxicity. (Pubmed Central) - Sep 20, 2024
Education on injection techniques and the use of single-dose autoinjectors/pens can mitigate ISR risk. ABCG2_rs2231137 variant carriers had borderline higher incidence of grade 3-4 neutropenia (OR: 4.14, 95% CI: 0.99-17.37, p
- || Retrospective data, Review, Journal, Metastases: Comparative efficacy of later-line therapies for metastatic colorectal cancer: a network meta-analysis of survival curves. (Pubmed Central) - Sep 20, 2024
TAS+bevacizumab emerged as the most dominant option and may be the preferred choice; with fruquintinib, regorafenib and TAS-102 monotherapy showing statistically significant but lower PFS and OS benefits. PROSPERO: CRD42022371953.
- | Enbrel (etanercept) / Pfizer, Amgen
Journal: Etanercept: A Potential Option in Refractory Complicated Neurocysticercosis. (Pubmed Central) - Sep 20, 2024
PROSPERO: CRD42022371953. No abstract available
- ||| Ibrance (palbociclib) / Pfizer, Kisqali (ribociclib) / Novartis, Verzenio (abemaciclib) / Eli Lilly
Journal, Adverse events, Real-world evidence, Real-world: A real-world pharmacovigilance study of QT interval prolongation and Torsades de Pointes associated with CDK4/6 inhibitors in breast cancer patients: findings from the FDA adverse event reporting system. (Pubmed Central) - Sep 20, 2024
Disproportionality analysis revealed that ribociclib was related to QTp/TdP...Palbociclib and abemaciclib had no correlation with QTP/TDP events...The QT interval was monitored before and after medication. Attention should be given to adjusting the drugson time.
- | Loqtorzi (toripalimab-tpzi) / Shanghai Junshi Biosci, Coherus Biosci, Stivarga (regorafenib) / Bayer
Trial primary completion date, Combination therapy, Metastases: SLOT: Regorafenib Alone or in Combination With Hypofractionated/Low-dose Radiotherapy Plus Toripalimab for Metastatic Colorectal Cancer (clinicaltrials.gov) - Sep 20, 2024
P2, N=90, Recruiting, Sponsor: Fudan University
Attention should be given to adjusting the drugson time. Trial primary completion date: Apr 2024 --> Apr 2025
- || Blincyto (blinatumomab) / Astellas, Amgen
Review, Journal: A critical review of management of allogeneic transplant-eligible adults with Ph+ acute lymphoblastic leukaemia. (Pubmed Central) - Sep 20, 2024
Can chemotherapy-free approaches, such as blinatumomab in conjunction with more potent TKIs, obviate the need for an allograft in high-risk patients?...Can salvage therapy and a subsequent allograft cure patients who relapse after not being transplanted in CR1? This manuscript reviews the latest data influencing contemporary management and discusses these controversies.
- | Trial primary completion date: Treatment of Rheumatoid Arthritis With DMARDs: Predictors of Response (clinicaltrials.gov) - Sep 20, 2024
P3, N=400, Recruiting, Sponsor: University of Nebraska
This manuscript reviews the latest data influencing contemporary management and discusses these controversies. Trial primary completion date: Mar 2026 --> Mar 2027
- | Granocyte (lenograstim) / Roche, Neupogen (filgrastim) / Kyowa Kirin, Amgen
Enrollment closed, Enrollment change: Continuous Versus Bolus Administration of G-CSF in Children With Cancer (clinicaltrials.gov) - Sep 20, 2024
P4, N=20, Active, not recruiting, Sponsor: Chang Gung Memorial Hospital
Trial primary completion date: Mar 2026 --> Mar 2027 Recruiting --> Active, not recruiting | N=40 --> 20
- || Biomarker, Trial completion date, Trial primary completion date: BOUQUET: A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors (clinicaltrials.gov) - Sep 20, 2024
P2, N=176, Active, not recruiting, Sponsor: Hoffmann-La Roche
Recruiting --> Active, not recruiting | N=40 --> 20 Trial completion date: Dec 2028 --> May 2028 | Trial primary completion date: May 2028 --> Feb 2028
- | Ibrance (palbociclib) / Pfizer
Journal, Metastases: Absolute lymphocyte count predicts efficacy of palbociclib in patients with metastatic luminal breast cancer. (Pubmed Central) - Sep 20, 2024
Trial completion date: Dec 2028 --> May 2028 | Trial primary completion date: May 2028 --> Feb 2028 ALC can serve as a predictor of palbociclib efficacy in patients with metastatic ER-positive, HER2-negative breast cancer.
- | Uplizna (inebilizumab-cdon) / Mitsubishi Tanabe, Amgen
Enrollment open: Inebilizumab in Acute Neuromyelitis Optica Spectrum Disorders (clinicaltrials.gov) - Sep 20, 2024
P=N/A, N=50, Recruiting, Sponsor: Xuanwu Hospital, Beijing
ALC can serve as a predictor of palbociclib efficacy in patients with metastatic ER-positive, HER2-negative breast cancer. Not yet recruiting --> Recruiting
- ||||||| HLX14 (denosumab biosimilar) / Fosun Pharma, Organon
Trial completion, Trial primary completion date: A Study to Evaluate the Efficacy and Safety of HLX14 vs. Denosumab Prolia (clinicaltrials.gov) - Sep 20, 2024
P3, N=514, Completed, Sponsor: Shanghai Henlius Biotech
Not yet recruiting --> Recruiting Active, not recruiting --> Completed | Trial primary completion date: Apr 2024 --> Dec 2023
- | Stivarga (regorafenib) / Bayer
Enrollment closed, Metastases: NEXT-REGIRI: Assessing a Regorafenib-irinotecan Combination Versus Regorafenib Alone in Metastatic Colorectal Cancer Patients (clinicaltrials.gov) - Sep 20, 2024
P3, N=66, Active, not recruiting, Sponsor: Institut du Cancer de Montpellier - Val d'Aurelle
Active, not recruiting --> Completed | Trial primary completion date: Apr 2024 --> Dec 2023 Recruiting --> Active, not recruiting
- | Neupogen (filgrastim) / Kyowa Kirin, Amgen, Zarxio (filgrastim-sndz) / Sandoz, Mylotarg (gemtuzumab ozogamicin) / Pfizer
Trial completion date, Trial primary completion date: Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome (clinicaltrials.gov) - Sep 20, 2024
P2, N=270, Recruiting, Sponsor: M.D. Anderson Cancer Center
Recruiting --> Active, not recruiting Trial completion date: Dec 2024 --> Dec 2026 | Trial primary completion date: Dec 2024 --> Dec 2026
- || Prolia (denosumab) / Amgen
Clinical, Retrospective data, Review, Journal: Effect of denosumab, an anti-osteoporosis drug, on vascular calcification: A meta-analysis. (Pubmed Central) - Sep 20, 2024
However, denosumab showed the effective effect on inhibiting VC in CKD patients undergoing dialysis. More large RCTs are needed to verify these results.
- | Prolia (denosumab) / Amgen
Journal, Surgery: Post-craniopharyngioma surgery hypocalcemia due to denosumab use for osteoporosis: A case report. (Pubmed Central) - Sep 20, 2024
More large RCTs are needed to verify these results. It underscores the necessity for clinicians to perform a thorough evaluation of the patient's overall health status, complete all requisite testing, pay particular attention to those in high-risk categories, and ensure serum calcium levels are monitored, along with conducting other essential tests, prior to and following each administration of denosumab.
- || maridebart cafraglutide (AMG 133) / Amgen
Trial completion: A Study to Evaluate AMG 133 in Chinese Participants With Obesity or Overweight (clinicaltrials.gov) - Sep 20, 2024
P1, N=20, Completed, Sponsor: Amgen
It underscores the necessity for clinicians to perform a thorough evaluation of the patient's overall health status, complete all requisite testing, pay particular attention to those in high-risk categories, and ensure serum calcium levels are monitored, along with conducting other essential tests, prior to and following each administration of denosumab. Active, not recruiting --> Completed
- | Ibrance (palbociclib) / Pfizer, Bavencio (avelumab) / EMD Serono
Trial primary completion date: ImmunoADAPT: Neoadjuvant Endocrine Therapy, Palbociclib, Avelumab in Estrogen Receptor Positive Breast Cancer (clinicaltrials.gov) - Sep 20, 2024
P2, N=33, Active, not recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Active, not recruiting --> Completed Trial primary completion date: Jul 2024 --> Mar 2025
- || Xtandi (enzalutamide capsule) / Pfizer, Astellas, Prolia (denosumab) / Amgen, Pluvicto (lutetium Lu 177 vipivotide tetraxetan) / Novartis
Clinical, Journal, Metastases: Lu-177 PSMA vs Comparator Treatments and Survival in Metastatic Castration-Resistant Prostate Cancer. (Pubmed Central) - Sep 20, 2024
Observed treatment effects on overall survival (OS) differed substantially in the first 2 randomized clinical trials of lutetium Lu 177 vipivotide tetraxetan (Lu-177) prostate-specific membrane antigen (PSMA) in metastatic castration-resistant prostate cancer...VISION randomized participants to receive treatment with or without Lu-177 PSMA in addition to physicians' choice of protocol-permitted treatments (PPT; approved hormonal treatments [such as abiraterone and enzalutamide], bisphosphonates, radiotherapy, denosumab, or glucocorticoids), excluding cabazitaxel...Findings of this secondary analysis of the TheraP and VISION randomized clinical trials suggest that the choice of comparator treatments (ie, cabazitaxel vs PPT) may explain the difference in the observed effect of Lu-177 PSMA on OS between the 2 trials. Causal inference methods such as RPSFTM and IPCW may help rule out crossover as a plausible explanation.
- || ivabradine / Generic mfg.
Clinical, Journal, Surgery: Ivabradine in the Prevention, and Reduction in Size, of Perioperative Myocardial Injury in Patients Undergoing Orthopedic Surgery for Acute Fracture. (Pubmed Central) - Sep 20, 2024
Starting ivabradine preoperatively in elderly patients requiring acute surgery for fracture did not result in a statistically significant difference in the incidence of perioperative myocardial injury. There was no statistically significant difference in morbidity, mortality, or adverse events between treatment groups.
- ||| Ibrance (palbociclib) / Pfizer, Xenical (orlistat) / Roche, GSK
Journal, Adverse events: Exploring the top 30 drugs associated with drug-induced constipation based on the FDA adverse event reporting system. (Pubmed Central) - Sep 20, 2024
The drug with the highest ranking was lenalidomide (7,730 cases, 4.55%), with the most prevalent drug class being antineoplastic and immunomodulating agents...However, four drugs (orlistat, nintedanib, palbociclib, and dimethyl fumarate) presented an unexpected risk of constipation. Ranked by signal values, sevelamer carbonate emerged as the drug with the strongest risk signal [reporting odds ratio (95% CI): 115.51 (110.14, 121.15); PRR (?2): 83.78 (191,709.73); EBGM (EB05): 82.63 (79.4); IC (IC025): 6.37 (4.70)]...The median TTO for orlistat was 3
- || Prolia (denosumab) / Amgen
Clinical, Retrospective data, Review, Journal: Efficacy and safety of denosumab and teriparatide versus oral bisphosphonates to treat postmenopausal osteoporosis: a systematic review and meta-analysis. (Pubmed Central) - Sep 20, 2024
In conclusion, our study suggests that teriparatide and denosumab demonstrate comparable or potentially superior efficacy and safety profiles compared to oral bisphosphonates for the treatment of postmenopausal osteoporosis. PROSPERO, identifier CRD42024508382.
- || Imdelltra (tarlatamab-dlle) / Amgen
Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date: DeLLphi-303: First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC) (clinicaltrials.gov) - Sep 20, 2024
P1, N=184, Active, not recruiting, Sponsor: Amgen
PROSPERO, identifier CRD42024508382. Recruiting --> Active, not recruiting | N=340 --> 184 | Trial completion date: Jun 2029 --> Aug 2028 | Trial primary completion date: Jun 2029 --> Aug 2028
- | Prolia (denosumab) / Amgen
New trial: Observation and comparison of the direct efficacy of denosumab and zoledronic acid on bone metastases (EUDRACT) - Sep 20, 2024
P=N/A, N=100, Completed, Sponsor: The 2nd Affiliated Hospital of Chongqing Medical University; The 2nd Affiliated Hospital of Chongqing Medical University
- | Prolia (denosumab) / Amgen
New trial, Real-world evidence, Real-world: Effect of denosumab on intervertebral fusion rate in postmenopausal osteoporosis patients: a multicenter, prospective, real-world study (EUDRACT) - Sep 20, 2024
P=N/A, N=284, Not yet recruiting, Sponsor: Tangdu Hospital, Air Force Medical University; Tangdu Hospital, Air Force Medical University
- | Neulasta (pegfilgrastim) / Roche
New trial: Study on the Efficacy and Safety of Pegfilgrastim in Primary Prevention of Chemotherapy-induced Neutropenia in Non-Hodgkin Lymphoma (EUDRACT) - Sep 20, 2024
P=N/A, N=50, Not yet recruiting, Sponsor: Anqing Municipal Hospital; Anqing Municipal Hospital
- | Prolia (denosumab) / Amgen
New P4 trial: Efficacy and safety evaluation of denosumab in maintenance hemodialysis patients witn osteoporosis:a randomized controlled, multicenter, optimal efficacy study (EUDRACT) - Sep 20, 2024
P4, N=294, Not yet recruiting, Sponsor: The Third Affiliated Hospital of Southern Medical University; The Third Affiliated Hospital of Southern Medical University
- | Uplizna (inebilizumab-cdon) / Mitsubishi Tanabe, Amgen
New P4 trial: Clinical Study of Inebilizumab Combined with Steroids for the Treatment of Neuromyelitis Optica Spectrum Disorder (EUDRACT) - Sep 20, 2024
P4, N=128, Recruiting, Sponsor: West China Hospital,Sichuan University; West China Hospital,Sichuan University
- | Prolia (denosumab) / Amgen
Enrollment open: A prospective randomized controlled study of Denosumab and zoledronic acid in the treatment of female osteoporotic fractures (EUDRACT) - Sep 20, 2024
P=N/A, N=300, Recruiting, Sponsor: Shanghai Jiaotong University School of Medicine Affiliated Ruijin Hospital; Shanghai Jiaotong University School of Medicine Affiliated Ruijin Hospital
Recruiting --> Active, not recruiting | N=340 --> 184 | Trial completion date: Jun 2029 --> Aug 2028 | Trial primary completion date: Jun 2029 --> Aug 2028 Not yet recruiting --> Recruiting
- | Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
Enrollment open: Combining bone-building medication with bone-building exercise in postmenopausal women with low bone mass (EUDRACT) - Sep 20, 2024
P4, N=102, Recruiting, Sponsor: Royal North Shore Hospital
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- || Aimovig (erenumab-aooe) / Amgen, Novartis
Trial completion date, Trial primary completion date: Multidisciplinary Translational Approach to Investigate Mechanisms Predictors & Prevention of Persistent PTH (clinicaltrials.gov) - Sep 19, 2024
P2, N=112, Recruiting, Sponsor: Mayo Clinic
Not yet recruiting --> Recruiting Trial completion date: Aug 2024 --> Aug 2025 | Trial primary completion date: Aug 2024 --> Aug 2025
- | New P2 trial: B2024-428-01: Second-line Systemic Therapy Combined with SBRT for HCC with Oligoprogression After Standard First-line Systemic Treatment (clinicaltrials.gov) - Sep 19, 2024
P2, N=70, Not yet recruiting, Sponsor: Sun Yat-sen University
- | zetomipzomib (KZR-616) / Kezar
Trial completion date, Trial primary completion date: A Study of Zetomipzomib (KZR-616) in Patients With Autoimmune Hepatitis (PORTOLA) (clinicaltrials.gov) - Sep 19, 2024
P2, N=24, Active, not recruiting, Sponsor: Kezar Life Sciences, Inc.
Trial completion date: Aug 2024 --> Aug 2025 | Trial primary completion date: Aug 2024 --> Aug 2025 Trial completion date: Mar 2025 --> Aug 2025 | Trial primary completion date: Sep 2024 --> Feb 2025
- ||| Imdelltra (tarlatamab-dlle) / Amgen
New P1 trial: Subcutaneous Tarlatamab in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-308) (clinicaltrials.gov) - Sep 19, 2024
P1, N=100, Not yet recruiting, Sponsor: Amgen
- | Trial completion date: Application of N-of-1 Rheumatoid Arthritis (clinicaltrials.gov) - Sep 19, 2024
P=N/A, N=18, Not yet recruiting, Sponsor: Tufts Medical Center
Trial completion date: Mar 2025 --> Aug 2025 | Trial primary completion date: Sep 2024 --> Feb 2025 Trial completion date: Jul 2025 --> Oct 2025
- | Polivy (polatuzumab vedotin-piiq) / Roche, Lunsumio (mosunetuzumab-axgb) / Roche
New P2 trial: Mosunetuzumab and Polatuzumab Vedotin With Split-Dose CHP Chemotherapy for Elderly Patients With Diffuse Large B-Cell Lymphoma (clinicaltrials.gov) - Sep 19, 2024
P2, N=31, Not yet recruiting, Sponsor: Medical College of Wisconsin
- |||| AZD8630 / AstraZeneca, Amgen
Enrollment open, Trial primary completion date: Levante: A Dose Range-Finding Study to Assess the Efficacy and Safety of Multiple Dose Levels of AZD8630 in Adults With Uncontrolled Asthma at Risk of Exacerbations (clinicaltrials.gov) - Sep 19, 2024
P2, N=516, Recruiting, Sponsor: AstraZeneca
Trial completion date: Jul 2025 --> Oct 2025 Not yet recruiting --> Recruiting | Trial primary completion date: May 2025 --> Mar 2026